Revista Argentina de Reumatología,
Journal Year:
2023,
Volume and Issue:
33(4)
Published: Jan. 18, 2023
Introducción:
el
lupus
eritematoso
sistémico
(LES)
es
una
enfermedad
sistémica
que
se
ha
asociado
a
mayor
severidad
con
la
infección
por
SARS-CoV-2.
Particularmente
alta
actividad
de
y
algunos
inmunosupresores
han
vinculado
peores
desenlaces.
Objetivos:
describir
las
características
SARS-CoV-2
en
pacientes
LES
Argentina
del
registro
SAR-COVID
establecer
los
factores
asociados
peor
desenlace
misma.
Materiales
métodos:
estudio
observacional.
Se
incluyeron
diagnóstico
confirmada
(RT-PCR
y/o
serología
positiva)
SAR-COVID.
Los
datos
recolectaron
desde
agosto
2020
hasta
marzo
2022.
El
midió
mediante
escala
ordinal
Organización
Mundial
Salud
(EO-OMS).
definió
COVID-19
severo
un
valor
EO-OMS
≥5.
Análisis
descriptivo,
test
T
Student,
U
Mann
Whitney
U,
ANOVA,
chi2
Fisher.
Regresión
logística
múltiple.
Resultados:
399
pacientes,
93%
sexo
femenino,
edad
media
40,9
años
(DE
12,2).
39,6%
tenía
al
menos
comorbilidad.
Al
momento
infección,
54,9%
recibía
glucocorticoides,
30,8%
3,3%
agentes
biológicos.
La
fue
leve
mayoría
casos,
mientras
4,6%
tuvo
curso
falleció.
Estos
últimos
presentaban
comorbilidades,
usaban
glucocorticoides
tenían
síndrome
antifosfolípido
(SAF)
frecuencia
infección.
En
análisis
multivariado,
hipertensión
arterial,
SAF
uso
asociaron
hospitalización
severa
muerte
(EO-OMS
≥5).
Conclusiones:
esta
cohorte
confirmada,
cursó
manera
sintomática,
22,1%
hospitalizado
5%
requirió
ventilación
mecánica.
mortalidad
cercana
3%.
SAF,
tener
arterial
significativamente
severo.
Life Sciences,
Journal Year:
2023,
Volume and Issue:
319, P. 121531 - 121531
Published: Feb. 27, 2023
SARS-CoV-2
virus
has
attracted
a
lot
of
attention
globally
due
to
the
autoimmune
and
inflammatory
processes
that
were
observed
during
development
Covid-19
disease.
Excessive
activation
immune
response
triggering
autoantibodies
synthesis
as
well
an
excessive
cytokines
onset
cytokine
storm
vital
role
in
disease
outcome
occurring
complications.
This
scenario
is
reminiscent
infiltration
lymphocytes
monocytes
specific
organs
increased
production
chemoattractants
noted
other
diseases.
The
main
goal
this
study
investigate
complex
occur
find
similarities
with
diseases
such
multiple
sclerosis
(MS),
acute
respiratory
distress
syndrome
(ARDS),
rheumatoid
arthritis
(RA)
Kawasaki
advance
existing
diagnostic
therapeutic
protocols.
therapy
Interferon-gamma
(IFN-γ)
use
S1P
receptor
modulators
showed
promising
results.
However,
there
are
many
unknowns
about
these
mechanisms
possible
novel
therapies.
Therefore,
inflammation
autoimmunity
triggered
by
should
be
further
investigated
improve
procedures
protocols
for
Covid-19.
Biomedicines,
Journal Year:
2025,
Volume and Issue:
13(2), P. 516 - 516
Published: Feb. 19, 2025
Introduction:
The
classification
of
antiphospholipid
syndrome
(APS)
comprises
clinical
criteria
(vascular
thrombosis
or
obstetric
complications
throughout
life)
and
laboratory
(antiphospholipid
antibodies
(aPLs)
positivity,
confirmed
at
least
twice
12-week
interval).
Methods:
In
100
patients
admitted
to
the
hospital
with
COVID-19
pneumonia,
pregnancy
were
recorded
during
stay
in
personal
medical
history.
They
tested
for
nine
types
aPLs
four
time
points
(admission,
deterioration,
discharge,
3-month
follow-up):
anticardiolipin
(aCL),
anti-β2-glycoproteinI
(anti-β2GPI),
antiphosphatidylserine/prothrombin
(aPS/PT)
isotypes
IgM/IgG/IgA.
Results:
During
hospitalization,
detected
once
51%
patients.
All
7%
deceased
negative
upon
admission,
only
one
patient
became
aCL
IgG
positive
as
his
condition
worsened.
83.3%
patients,
intrahospital
was
not
related
aPLs.
One
pulmonary
artery
cerebral
given
an
APS
diagnosis
(triple
positivity
on
double
follow-up).
Personal
anamnesis
(PA)
thromboembolism
verified
10
all
whom
admission;
however,
transition
discharge
(as
disease
subsided)
seen
60%
patients:
three
six
arterial
(at
follow-up,
two
did
appear,
negativized)
deep
vein
(one
follow-up
diagnosed
APS,
negativized,
appear).
At
majority
class
(58.8%).
Unexpectedly,
decreased,
anti-β2GPI
(linked
thromboses)
newly
(14.9%),
(20.8%).
Conclusion:
incidence
our
cohort
2.0%,
whereas
general
population,
it
ranges
from
0.001%
0.002%.
might
have
increased
even
more
if
aPLs-positive
thrombosis/history
had
attended
follow-up.
Recommendation:
severe
post-COVID
should
be
evaluated
current/previous
twice:
admission
then
retested
3
months
later
cases
order
appropriate
therapy.
Rheumatology Science and Practice,
Journal Year:
2024,
Volume and Issue:
62(1), P. 32 - 54
Published: Feb. 29, 2024
The
pandemic
of
coronavirus
disease
2019
(COVID-19),
etiologically
related
to
the
SARS-CoV-2
virus
(severe
acute
respiratory
syndrome
coronavirus-2),
has
drawn
attention
new
clinical
and
fundamental
problems
in
immunopathology
human
diseases
associated
with
virus-induced
autoimmunity
autoinflammation.
provision
that
“the
experience
gained
rheumatology
process
studying
pathogenetic
mechanisms
pharmacotherapy
immunoinflammatory
rheumatic
as
most
common
severe
forms
autoimmune
autoinflammatory
pathology
humans
will
be
demand
for
deciphering
nature
pathological
processes
underlying
COVID-19
developing
approaches
effective
pharmacotherapy”
was
confirmed
numerous
studies
conducted
over
next
3
years
midst
pandemic.
main
focus
on
a
critical
analysis
data
regarding
role
inflammation,
which
basis
pathogenesis
immune-mediated
context
COVID-19.
Life,
Journal Year:
2022,
Volume and Issue:
12(11), P. 1918 - 1918
Published: Nov. 18, 2022
Coronavirus
disease
2019
(COVID-19)
is
an
infectious
viral
caused
by
Severe
Acute
Respiratory
Syndrome
2
(SARS-CoV-2).
It
known
that
infection
with
SARS-CoV-2
can
lead
to
various
autoimmune
and
autoinflammatory
diseases.
There
are
few
reports
in
the
literature
on
association
between
diseases,
number
of
has
been
increasing
since
2020.
Autoimmune
diseases
infections
intertwined
several
ways.
Both
conditions
immune-mediated
tissue
damage,
immune
response
accompanied
increased
secretion
inflammatory
cytokines
both
be
treated
using
immunomodulatory
drugs.
Patients
certain
such
as
systemic
lupus
erythematosus,
rheumatoid
arthritis,
type
1
diabetes,
cardiac
sarcoidosis,
idiopathic
pulmonary
fibrosis,
hepatitis,
multiple
sclerosis
others,
more
susceptible
infection,
either
because
active
or
medications
used
treat
it.
Conversely,
also
cause
In
this
paper,
we
describe
development
after
COVID-19
recovery
from
people
Pathogens and Immunity,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: June 26, 2023
Coronavirus
disease
2019
(COVID-19)
has
had
profound
effects
on
the
health
of
individuals
and
healthcare
systems
worldwide.
While
workers
frontlines
have
fought
to
quell
multiple
waves
infection,
efforts
larger
research
community
changed
arch
this
pandemic
as
well.
This
review
will
focus
biomarker
discovery
other
identify
features
that
predict
outcomes,
in
so
doing,
possible
effector
passenger
mechanisms
adverse
outcomes.
Identifying
measurable
soluble
factors,
cell-types,
clinical
parameters
a
patient’s
course
legacy
for
study
immunologic
responses,
especially
stimuli,
which
induce
an
overactive,
yet
ineffectual
immune
system.
As
prognostic
biomarkers
were
identified,
some
served
represent
pathways
therapeutic
interest
trials.
The
conditions
created
urgency
accelerated
target
identification
validation.
Collectively,
these
COVID-19
studies
biomarkers,
efficacy
revealed
responses
stimuli
are
more
heterogeneous
than
previously
assumed.
Understanding
genetic
acquired
mediate
divergent
outcomes
response
global
exposure
is
ongoing
ultimately
improve
our
preparedness
future
pandemics,
well
impact
preventive
approaches
diseases.
Circulation Research,
Journal Year:
2023,
Volume and Issue:
132(10), P. 1358 - 1373
Published: May 11, 2023
COVID-19
has
become
the
first
modern-day
pandemic
of
historic
proportion,
affecting
>600
million
individuals
worldwide
and
causing
>6.5
deaths.
While
acute
infection
had
devastating
consequences,
postacute
sequelae
SARS-CoV-2
appears
to
be
a
its
own,
impacting
up
one-third
survivors
often
symptoms
suggestive
cardiovascular
phenomena.
This
review
will
highlight
suspected
pathophysiology
SARS-CoV-2,
influence
on
system,
potential
treatment
strategies.
Journal of the American Heart Association,
Journal Year:
2024,
Volume and Issue:
13(18)
Published: Sept. 11, 2024
Population
studies
have
suggested
that
viral
infections
may
be
contributing
to
risk
of
ischemic
stroke,
although
the
mechanisms
for
this
are
unclear.
In
review,
we
examine
epidemiological
evidence
supporting
involvement
diseases,
including
influenza,
COVID‐19,
chronic
herpesvirus
infections,
and
hepatitis
C
in
current
trends
stroke
incidence.
To
support
these
associations,
highlight
virus–host
interactions
critical
context
direct
effects
acute
persistent
on
vascular
function,
inflammation,
thrombosis.
Additionally,
evaluate
systemic
changes
occur
during
infection
can
predispose
individuals
alterations
blood
pressure
regulation,
coagulation,
lipid
metabolism.
Our
review
emphasizes
need
further
elucidate
precise
involved
risk.
Future
research
will
inform
development
targeted
interventions
prevention
diseases.